- Home
- CHRS vs IPHA Comparison
CHRS vs IPHA Comparison
Compare CHRS & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- IPHA
- Stock Information
- Founded
- CHRS 2010
- IPHA 1999
- Country
- CHRS United States
- IPHA France
- Employees
- CHRS N/A
- IPHA N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- IPHA Biotechnology: Pharmaceutical Preparations
- Sector
- CHRS Health Care
- IPHA Health Care
- Exchange
- CHRS Nasdaq
- IPHA Nasdaq
- Market Cap
- CHRS 84.2M
- IPHA 160.1M
- IPO Year
- CHRS 2014
- IPHA 2019
- Fundamental
- Price
- CHRS $0.82
- IPHA N/A
- Analyst Decision
- CHRS Buy
- IPHA Strong Buy
- Analyst Count
- CHRS 3
- IPHA 1
- Target Price
- CHRS $4.68
- IPHA $11.00
- AVG Volume (30 Days)
- CHRS 1.3M
- IPHA 11.7K
- Earning Date
- CHRS 08-07-2025
- IPHA 03-27-2025
- Dividend Yield
- CHRS N/A
- IPHA N/A
- EPS Growth
- CHRS N/A
- IPHA N/A
- EPS
- CHRS N/A
- IPHA N/A
- Revenue
- CHRS $272,251,000.00
- IPHA $20,831,349.00
- Revenue This Year
- CHRS N/A
- IPHA $209.83
- Revenue Next Year
- CHRS $106.56
- IPHA $83.15
- P/E Ratio
- CHRS $1.87
- IPHA N/A
- Revenue Growth
- CHRS 19.87
- IPHA N/A
- 52 Week Low
- CHRS $0.66
- IPHA $1.29
- 52 Week High
- CHRS $2.43
- IPHA $3.51
- Technical
- Relative Strength Index (RSI)
- CHRS 53.13
- IPHA 39.24
- Support Level
- CHRS $0.72
- IPHA $1.71
- Resistance Level
- CHRS $0.77
- IPHA $1.92
- Average True Range (ATR)
- CHRS 0.04
- IPHA 0.09
- MACD
- CHRS 0.01
- IPHA -0.00
- Stochastic Oscillator
- CHRS 91.62
- IPHA 37.93
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.